First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

[1]  Y. Seimbille,et al.  Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors , 2022, Pharmaceuticals.

[2]  S. de Placido,et al.  Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors , 2022, The Journal of Nuclear Medicine.

[3]  A. Phan,et al.  Neuroendocrine Tumors: a Relevant Clinical Update , 2022, Current Oncology Reports.

[4]  X. Xing,et al.  Head-to-Head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study , 2022, Frontiers in Oncology.

[5]  Y. Yatabe,et al.  Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors , 2022, Cancers.

[6]  E. Pescarmona,et al.  Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Ayano Doi,et al.  Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy , 2021, Pharmaceutics.

[8]  J. Constanzo,et al.  Revisiting the Radiobiology of Targeted Alpha Therapy , 2021, Frontiers in Medicine.

[9]  S. Hernot,et al.  Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals. , 2021, Current opinion in chemical biology.

[10]  A. Aerts,et al.  Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. , 2021, Nuclear medicine and biology.

[11]  Y. Seimbille,et al.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC , 2021, Pharmaceutics.

[12]  O. Nilsson,et al.  Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT , 2021, Cancers.

[13]  R. Engelman,et al.  Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Satya N. Das,et al.  Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? , 2021, Current Oncology Reports.

[15]  Jianming Xu,et al.  A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors , 2021, The Journal of Nuclear Medicine.

[16]  Xiaoyuan Chen,et al.  177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer , 2020, Clinical Cancer Research.

[17]  W. Brenner,et al.  Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model , 2020, The Journal of Nuclear Medicine.

[18]  Y. Arano.  Renal brush border strategy: A developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides. , 2020, Nuclear medicine and biology.

[19]  M. de Jong,et al.  Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward , 2020, Current topics in medicinal chemistry.

[20]  E. Moros,et al.  Development of Targeted Alpha Particle Therapy for Solid Tumors , 2019, Molecules.

[21]  Jianming Xu,et al.  Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study , 2019, The Journal of Nuclear Medicine.

[22]  Serge K. Lyashchenko,et al.  Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan , 2019, Clinical Cancer Research.

[23]  D. Kennaway.  Melatonin research in mice: a review , 2019, Chronobiology international.

[24]  F. Saad,et al.  Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review , 2018, JAMA oncology.

[25]  A. Grossman,et al.  Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy , 2018, Neuroendocrinology.

[26]  Justin J. Wilson,et al.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches. , 2018, Cancer biotherapy & radiopharmaceuticals.

[27]  E. Krenning,et al.  Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Sören Mattsson,et al.  IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms , 2017, EJNMMI Research.

[29]  D. Metz,et al.  Efficacy of Peptide Receptor Radionuclide Therapy in a United States–Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis , 2017, Pancreas.

[30]  M. de Jong,et al.  Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome? , 2017, EJNMMI Radiopharmacy and Chemistry.

[31]  G. Nicolas,et al.  Somatostatin Receptor Antagonists for Imaging and Therapy , 2017, The Journal of Nuclear Medicine.

[32]  R. Schibli,et al.  Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β−-Particle, and Auger Electron Emitters , 2017, The Journal of Nuclear Medicine.

[33]  M. Pavel,et al.  Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs , 2016, Journal of global oncology.

[34]  E. Scarpi,et al.  Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  C. Tinelli,et al.  Long-term results of PRRT in advanced bronchopulmonary carcinoid , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  O. Desouky,et al.  Targeted and non-targeted effects of ionizing radiation , 2015 .

[37]  M. Jong,et al.  Somatostatin Analogues: From Research to Clinical Practice , 2015 .

[38]  W. Weber,et al.  Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study , 2014, The Journal of Nuclear Medicine.

[39]  W. Breeman,et al.  Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs. , 2014, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[40]  W. Breeman,et al.  Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC. , 2013, Current topics in medicinal chemistry.

[41]  P. MacDonald,et al.  SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells. , 2012, American journal of physiology. Endocrinology and metabolism.

[42]  W. Weber,et al.  Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications , 2012, The Journal of Nuclear Medicine.

[43]  H. Song,et al.  A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry , 2012, Physics in medicine and biology.

[44]  T. Honma,et al.  Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry , 2012, Acta histochemica et cytochemica.

[45]  Wolfgang A Weber,et al.  PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference , 2011, The Journal of Nuclear Medicine.

[46]  Kjell Öberg,et al.  Current knowledge on diagnosis and staging of neuroendocrine tumors , 2011, Cancer and Metastasis Reviews.

[47]  J. Humm,et al.  Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody , 2011, Physics in medicine and biology.

[48]  Jean E Rivier,et al.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. , 2008, Journal of medicinal chemistry.

[49]  R. Senekowitsch-Schmidtke,et al.  Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors , 2008, Clinical Cancer Research.

[50]  M. Brechbiel.  Targeted α-therapy: past, present, future? , 2007 .

[51]  W. Oyen,et al.  Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  T. Visser,et al.  Localisation and mechanism of renal retention of radiolabelled somatostatin analogues , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[53]  D. Kennaway,et al.  Melatonin in mice: rhythms, response to light, adrenergic stimulation, and metabolism. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[54]  S. Kennel,et al.  Comparison of 225actinium chelates: tissue distribution and radiotoxicity. , 1999, Nuclear medicine and biology.

[55]  Marion de Jong,et al.  Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..